{"id":"cciiv4","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"<5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ccIIV4 is a quadrivalent inactivated influenza vaccine produced using cell culture technology rather than egg-based methods. It contains inactivated antigens from four influenza virus strains (two A subtypes and two B lineages) and works by inducing humoral and cellular immune responses to provide protection against seasonal influenza infection.","oneSentence":"ccIIV4 is a cell-culture-derived inactivated influenza vaccine that stimulates immune responses against multiple influenza virus strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:17:32.905Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":"Influenza","enrollment":366},{"nctId":"NCT06518577","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccinations","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-09","conditions":"Influenza","enrollment":605},{"nctId":"NCT03743688","phase":"","title":"Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-12-04","conditions":"Influenza, Influenza, Human, Vaccine Reaction","enrollment":10},{"nctId":"NCT02967393","phase":"PHASE4","title":"Influenza Vaccine Feasibility Study in Children With Persistent Asthma","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-10-10","conditions":"Asthmatic","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Flucelvax"],"phase":"marketed","status":"active","brandName":"ccIIV4","genericName":"ccIIV4","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ccIIV4 is a cell-culture-derived inactivated influenza vaccine that stimulates immune responses against multiple influenza virus strains. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}